Vaxfectin®, a cationic lipid-based adjuvant for protein-based influenza vaccines

Vaccine

Volumn 27, Issue 46, 2009, Pages 6399-6403

  Hartikka, Jukka ^a   Bozoukova, Vesselina ^a   Yang, Catherine K ^a   Ye, Ming ^a   Rusalov, Denis ^a   Shlapobersky, Mark ^a   Vilalta, Adrian ^a   Wei, Qun ^a   Rolland, Alain ^a   Smith, Larry R ^a  

^a VICAL INC   (United States)

Author keywords

Adjuvant; Cationic lipid; Vaccine

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 5; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIPLE VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VAXFECTIN; CATION; IMMUNOGLOBULIN G; PHOSPHATIDYLETHANOLAMINE; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMORAL IMMUNITY; IN VIVO STUDY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TH1 CELL; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; ORTHOMYXOVIRUS INFECTION; SPLEEN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIGENS, VIRAL; CATIONS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; INFLUENZA VACCINES; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; PHOSPHATIDYLETHANOLAMINES; SPLEEN; TH1 CELLS;

EID: 70350060159     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.014     Document Type: Article

References (24)

1. Hartikka J., Bozoukova V., Ferrari M., Sukhu L., Enas J., Sawdey M., et al. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 19 15-16 (2001) 1911-1923
2. Reyes L., Hartikka J., Bozoukova V., Sukhu L., Nishioka W., Singh G., et al. Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization. Vaccine 19 27 (2001) 3778-3786
3. Hermanson G., Whitlow V., Parker S., Tonsky K., Rusalov D., Ferrari M., et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci USA 101 37 (2004) 13601-13606
4. Jimenez G.S., Planchon R., Wei Q., Rusalov D., Geall A., Enas J., et al. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccine 3 5 (2007) 157-164
5. Lalor P.A., Webby R.J., Morrow J., Rusalov D., Kaslow D.C., Rolland A., et al. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis 197 12 (2008) 1643-1652
6. Pan C.H., Jimenez G.S., Nair N., Wei Q., Adams R.J., Polack F.P., et al. Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus. Clin Vaccine Immunol 15 8 (2008) 1214-1221
7. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 9587 (2007) 580-589
8. Levie K., Leroux-Roels I., Hoppenbrouwers K., Kervyn A.D., Vandermeulen C., Forgus S., et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 198 5 (2008) 642-649
9. Ott G., Barchfeld G.L., and Van Nest G. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 13 16 (1995) 1557-1562
10. Stephenson I., Bugarini R., Nicholson K.G., Podda A., Wood J.M., Zambon M.C., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 191 8 (2005) 1210-1215
11. Wack A., Baudner B.C., Hilbert A.K., Manini I., Nuti S., Tavarini S., et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26 4 (2008) 552-561
12. Bungener L., Geeraedts F., Ter Veer W., Medema J., Wilschut J., and Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26 19 (2008) 2350-2359
13. Guy B., Pascal N., Francon A., Bonnin A., Gimenez S., Lafay-Vialon E., et al. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine 19 13-14 (2001) 1794-1805
14. Joseph A., Itskovitz-Cooper N., Samira S., Flasterstein O., Eliyahu H., Simberg D., et al. A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Vaccine 24 18 (2006) 3990-4006
15. Riedl K., Riedl R., von Gabain A., Nagy E., and Lingnau K. The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. Vaccine 26 27-28 (2008) 3461-3468
16. Hartikka J., Geall A., Bozoukova V., Kurniadi D., Rusalov D., Enas J., et al. Physical characterization and in vivo evaluation of poloxamer-based DNA vaccine formulations. J Gene Med 10 7 (2008) 770-782
17. Korsholm K.S., Agger E.M., Foged C., Christensen D., Dietrich J., Andersen C.S., et al. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 121 2 (2007) 216-226
18. Foged C., Arigita C., Sundblad A., Jiskoot W., Storm G., and Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 22 15-16 (2004) 1903-1913
19. Nakanishi T., Kunisawa J., Hayashi A., Tsutsumi Y., Kubo K., Nakagawa S., et al. Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins. Biochem Biophys Res Commun 240 3 (1997) 793-797
20. Walker C., Selby M., Erickson A., Cataldo D., Valensi J.P., and Van Nest G.V. Cationic lipids direct a viral glycoprotein into the class I major histocompatibility complex antigen-presentation pathway. Proc Natl Acad Sci USA 89 17 (1992) 7915-7918
21. Vangasseri D.P., Cui Z., Chen W., Hokey D.A., Falo Jr. L.D., and Huang L. Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol 23 5 (2006) 385-395
22. Yan W., Chen W., and Huang L. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol Immunol 44 15 (2007) 3672-3681
23. Huber V.C., McKeon R.M., Brackin M.N., Miller L.A., Keating R., Brown S.A., et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13 9 (2006) 981-990
24. Feng J.Q., Mozdzanowska K., and Gerhard W. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J Virol 76 3 (2002) 1369-1378